Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 1/20 | 0.60 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.60 |
| ▸ | TSHR | P16473 | 1/20 | 0.60 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.60 |
| ▸ | LMNA | P02545 | 1/20 | 0.58 |
| ▸ | QPCT | Q16769 | 1/20 | 0.54 |
| ▸ | QPCTL | Q9NXS2 | 1/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.50 |
| ▸ | MEN1 | O00255 | 2/20 | 0.50 |
| ▸ | POLB | P06746 | 1/20 | 0.48 |
| ▸ | HRH4 | Q9H3N8 | 2/20 | 0.46 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5036734 | 0.89 | CYP3A4 (0.64) | CYP3A4CYP2D6TSHRCYP2C19LMNA | |
| SCHEMBL17481128 | 0.83 | CYP3A4 (0.82) | CYP3A4CYP2D6TSHRCYP2C19LMNA | |
| SCHEMBL9058710 | 0.82 | CYP3A4 (0.68) | CYP3A4CYP2D6TSHRCYP2C19LMNA | |
| SCHEMBL13033285 | 0.81 | CYP3A4 (0.74) | CYP3A4CYP2D6TSHRCYP2C19LMNA | |
| SCHEMBL18381362 | 0.79 | CYP3A4 (0.64) | CYP3A4CYP2D6TSHRCYP2C19LMNA | |
| SCHEMBL18381205 | 0.78 | CYP3A4 (0.74) | CYP3A4CYP2D6TSHRCYP2C19LMNA | |
| SCHEMBL13033264 | 0.78 | QPCT (0.71) | CYP3A4CYP2D6TSHRCYP2C19LMNA | |
| SCHEMBL17481134 | 0.78 | CYP3A4 (0.78) | CYP3A4CYP2D6TSHRCYP2C19LMNA | |
| SCHEMBL17483163 | 0.78 | CYP3A4 (0.78) | CYP3A4CYP2D6TSHRCYP2C19LMNA | |
| SCHEMBL17483288 | 0.77 | QPCT (0.66) | CYP3A4CYP2D6TSHRCYP2C19LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100008855-A1 | Production and Use of Novel Peptide-Based Agents with Bispecific Antibodies | IMMUNOMEDICS, INC. (US) | 2010-01-14 | — | — | US | disclosed |
| US-7300655-B2 | Alpha-fetoprotein Immu31 antibodies and fusion proteins and methods of use thereof | IMMUNOMEDICS, INC. (US) | 2007-11-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100008855-A1 | Production and Use of Novel Peptide-Based Agents with Bispecific Antibodies | FCGR3B, IGSF11, RNPEP | CYP3A4 4499/4885CYP2D6 3997/4885TSHR 1346/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.